BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De La Fuente A, Zilio S, Caroli J, Van Simaeys D, Mazza EMC, Ince TA, Bronte V, Bicciato S, Weed DT, Serafini P. Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. Sci Transl Med 2020;12:eaav9760. [PMID: 32554710 DOI: 10.1126/scitranslmed.aav9760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Arlauckas S, Oh N, Li R, Weissleder R, Miller MA. Macrophage imaging and subset analysis using single-cell RNA sequencing. Nanotheranostics 2021;5:36-56. [PMID: 33391974 DOI: 10.7150/ntno.50185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Vanhaver C, van der Bruggen P, Bruger AM. MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer. J Clin Med 2021;10:2872. [PMID: 34203451 DOI: 10.3390/jcm10132872] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Wei J, Gilboa E, Calin GA, Heimberger AB. Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. Front Oncol 2021;11:682129. [PMID: 34532286 DOI: 10.3389/fonc.2021.682129] [Reference Citation Analysis]
4 Liu B, Zhang X, Li J, Yao S, Lu Y, Cao B, Liu Z. X-ray-Triggered CO Release Based on GdW10/MnBr(CO)5 Nanomicelles for Synergistic Radiotherapy and Gas Therapy. ACS Appl Mater Interfaces 2022;14:7636-45. [PMID: 35109649 DOI: 10.1021/acsami.1c22575] [Reference Citation Analysis]
5 Dai X, Ren L, Liu M, Cai H, Zhang H, Gong Q, Gu Z, Luo K. Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. Nano Today 2021;39:101163. [DOI: 10.1016/j.nantod.2021.101163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tian S, Welte T, Mai J, Liu Y, Ramirez M, Shen H. Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells. Front Pharmacol 2021;12:752934. [PMID: 35126104 DOI: 10.3389/fphar.2021.752934] [Reference Citation Analysis]
7 Shigdar S, Schrand B, Giangrande PH, de Franciscis V. Aptamers: Cutting edge of cancer therapies. Mol Ther 2021;29:2396-411. [PMID: 34146729 DOI: 10.1016/j.ymthe.2021.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lewis T, Giroux E, Jovic M, Martic-Milne S. Localized surface plasmon resonance aptasensor for selective detection of SARS-CoV-2 S1 protein. Analyst 2021;146:7207-17. [PMID: 34724009 DOI: 10.1039/d1an01458g] [Reference Citation Analysis]
9 Van Simaeys D, De La Fuente A, Zilio S, Zoso A, Kuznetsova V, Alcazar O, Buchwald P, Grilli A, Caroli J, Bicciato S, Serafini P. RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human β cells. Nat Commun 2022;13:1815. [PMID: 35383192 DOI: 10.1038/s41467-022-29377-3] [Reference Citation Analysis]
10 Welte T, Mai J, Zhang Z, Tian S, Zhang G, Xu Y, Zhang L, Chen SS, Wang T, Shen H. A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells. iScience 2021;24:103349. [PMID: 34825135 DOI: 10.1016/j.isci.2021.103349] [Reference Citation Analysis]
11 Krishnamoorthy M, Gerhardt L, Maleki Vareki S. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy. Cells 2021;10:1170. [PMID: 34065010 DOI: 10.3390/cells10051170] [Cited by in F6Publishing: 2] [Reference Citation Analysis]